The Cooper Companies, based in San Ramon, California, employs 15,000 and operates through CooperVision, focused on contact lenses, and CooperSurgical, specializing in fertility and women's health solutions.
Based on our analysis, The Cooper Companies has received a fairly valued rating of 2 out of 5 stars from Cashu, indicating that the stock may not be optimally priced for potential investors. Several key financial ratios suggest areas where Cooper Companies does not outperform its sector peers, contributing to this valuation.
The price-to-earnings (PE) ratio for Cooper Companies stands at 36.08, significantly higher than the sector average of 13.90. A high PE ratio may indicate that the stock is overvalued relative to its earnings, making it less attractive in comparison to its competitors.
Additionally, the company’s return on equity (ROE) is 4.85, outperforming the sector's negative average of -75.69. However, the relatively low ROE suggests that Cooper is not generating strong returns on shareholder equity, which could be a concern for investors looking for growth.
While Cooper Companies has a net profit margin of 10.07, which is strong compared to the sector's alarming -138.43, the absence of a dividend yield (0.00) versus the sector average of 0.19 may discourage income-focused investors. This lack of dividends could signal that the company is reinvesting profits rather than returning value to shareholders, which may not appeal to all investors.
In summary, while Cooper Companies shows some positive metrics, its high PE ratio and zero dividend yield contribute to its fairly valued assessment.
This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.
📡️ Health Care
Overvalued
More Signals
Feature in Progress
This section is under development. Check back soon for updates!